Albiglutide efficacy and safety in the Latino/Hispanic subpopulation for the integrated phase III program.

about

Albiglutide efficacy and safety in the Latino/Hispanic subpopulation for the integrated phase III program.

Item

http://www.wikidata.org/entity/Q47588862

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh-hant

name

Albiglutide efficacy and safet ...... integrated phase III program.

@en

Albiglutide efficacy and safet ...... integrated phase III program.

@nl

type

Item

label

Albiglutide efficacy and safet ...... integrated phase III program.

@en

Albiglutide efficacy and safet ...... integrated phase III program.

@nl

prefLabel

Albiglutide efficacy and safet ...... integrated phase III program.

@en

Albiglutide efficacy and safet ...... integrated phase III program.

@nl

P1476

Albiglutide efficacy and safet ...... integrated phase III program.

@en

P2093

Angela Jones-Leone

http://www.w3.org/2001/XMLSchema#string

Antonio Nino

http://www.w3.org/2001/XMLSchema#string

Jaime A Davidson

http://www.w3.org/2001/XMLSchema#string

Rickey R Reinhardt

http://www.w3.org/2001/XMLSchema#string

Sergio Forero-Schwanhaeuser

http://www.w3.org/2001/XMLSchema#string

Timothy H Wilson

http://www.w3.org/2001/XMLSchema#string

P2860

Glucose control in diabetes: the impact of racial differences on monitoring and outcomes

Ethnic disparities: control of glycemia, blood pressure, and LDL cholesterol among US adults with type 2 diabetes.

Disparities in A1C levels between Hispanic and non-Hispanic white adults with diabetes: a meta-analysis.

Prevalence of diabetes among Hispanics/Latinos from diverse backgrounds: the Hispanic Community Health Study/Study of Latinos (HCHS/SOL).

The biology of incretin hormones.

Pharmacodynamics, pharmacokinetics, safety, and tolerability of albiglutide, a long-acting glucagon-like peptide-1 mimetic, in patients with type 2 diabetes.

Gastrointestinal adverse events of glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes: a systematic review and network meta-analysis.

Exenatide once weekly for the treatment of type 2 diabetes: effectiveness and tolerability in patient subpopulations

Efficacy and safety of once-weekly GLP-1 receptor agonist albiglutide (HARMONY 2): 52 week primary endpoint results from a randomised, placebo-controlled trial in patients with type 2 diabetes mellitus inadequately controlled with diet and exercise.

Potential of albiglutide, a long-acting GLP-1 receptor agonist, in type 2 diabetes: a randomized controlled trial exploring weekly, biweekly, and monthly dosing

P304

849-857

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1080/00325481.2017.1387473

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

129

http://www.w3.org/2001/XMLSchema#string

P577

2017-10-30T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29083275

http://www.w3.org/2001/XMLSchema#string